Literature DB >> 29076373

Clinical characteristics and muscle glycogen concentrations in warmblood horses with polysaccharide storage myopathy.

Susannah S Lewis, Anne M Nicholson, Zoë J Williams, Stephanie J Valberg.   

Abstract

OBJECTIVE To characterize clinical findings for polysaccharide storage myopathy (PSSM) in warmblood horses with type 1 PSSM (PSSM1; caused by mutation of the glycogen synthase 1 gene) and type 2 PSSM (PSSM2; unknown etiology). SAMPLE Database with 3,615 clinical muscle biopsy submissions. PROCEDURES Reported clinical signs and serum creatine kinase (CK) and aspartate aminotransferase (AST) activities were retrospectively analyzed for horses with PSSM1 (16 warmblood and 430 nonwarmblood), horses with PSSM2 (188 warmblood and 646 nonwarmblood), and warmblood horses without PSSM (278). Lameness examinations were reviewed for 9 warmblood horses with PSSM2. Muscle glycogen concentrations were evaluated for horses with PSSM1 (14 warmblood and 6 nonwarmblood), warmblood horses with PSSM2 (13), and horses without PSSM (10 warmblood and 6 nonwarmblood). RESULTS Rhabdomyolysis was more common for horses with PSSM1 (12/16 [75%] warmblood and 223/303 [74%] nonwarmblood) and nonwarmblood horses with PSSM2 (221/436 [51%]) than for warmblood horses with PSSM2 (39/147 [27%]). Gait abnormality was more common in warmblood horses with PSSM2 (97/147 [66%]) than in warmblood horses with PSSM1 (1/16 [7%]), nonwarmblood horses with PSSM2 (176/436 [40%]), and warmblood horses without PSSM (106/200 [53%]). Activities of CK and AST were similar in warmblood horses with and without PSSM2. Muscle glycogen concentrations in warmblood and nonwarmblood horses with PSSM1 were significantly higher than concentrations in warmblood horses with PSSM2. CONCLUSIONS AND CLINICIAL RELEVANCE Rhabdomyolysis and elevated muscle glycogen concentration were detected in horses with PSSM1 regardless of breed. Most warmblood horses with PSSM2 had stiffness and gait abnormalities with CK and AST activities and muscle glycogen concentrations within reference limits.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29076373     DOI: 10.2460/ajvr.78.11.1305

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Clinical and histopathological features of myofibrillar myopathy in Warmblood horses.

Authors:  S J Valberg; A M Nicholson; S S Lewis; R A Reardon; C J Finno
Journal:  Equine Vet J       Date:  2017-06-26       Impact factor: 2.888

2.  Candidate gene expression and coding sequence variants in Warmblood horses with myofibrillar myopathy.

Authors:  Zoë J Williams; Deborah Velez-Irizarry; Jessica L Petersen; Julien Ochala; Carrie J Finno; Stephanie J Valberg
Journal:  Equine Vet J       Date:  2020-06-25       Impact factor: 2.888

3.  Muscle glycogen concentrations and response to diet and exercise regimes in Warmblood horses with type 2 Polysaccharide Storage Myopathy.

Authors:  Zoë J Williams; Megan Bertels; Stephanie J Valberg
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

4.  Genomic Divergence in Swedish Warmblood Horses Selected for Equestrian Disciplines.

Authors:  Michela Ablondi; Susanne Eriksson; Sasha Tetu; Alberto Sabbioni; Åsa Viklund; Sofia Mikko
Journal:  Genes (Basel)       Date:  2019-11-27       Impact factor: 4.096

5.  Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis.

Authors:  Stephanie J Valberg; Carrie J Finno; Marisa L Henry; Melissa Schott; Deborah Velez-Irizarry; Sichong Peng; Erica C McKenzie; Jessica L Petersen
Journal:  Equine Vet J       Date:  2020-10-29       Impact factor: 2.888

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.